Head-to-head · WeighScore
Belle Health vs Virta Health
The verdict
Belle Health takes it — 77/100 to 59.7/100.
Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | Virta Health |
|---|---|---|
| WeighScore | 77/100 | 59.7/100 |
| Grade | C+ | C |
| Scorecard rank | #48 | #337 |
| Semaglutide | $119/mo | Not disclosed |
| Tirzepatide | $199/mo (all doses, 3-month plan, compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #48 · C+
Strengths
- Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
- Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
- Free weekly registered-dietitian sessions included
- Operating since 2017
- LegitScript Certified
Where it loses points
- $199 tirzepatide price requires a 3-month bundle commitment
- Compounded medications are not FDA-approved
- Multi-pharmacy model — formulations may differ across orders
- FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Graded #337 · C
Strengths
- Offers a Responsible Prescribing track with optimized GLP-1 use
- Clinically monitored medication off-ramp toward nutrition therapy
- Nutrition-first model shown to rival GLP-1 weight loss (about 13% at 1 year)
- Provided at no cost to members through employers and health plans
- Strong evidence base for diabetes reversal and metabolic health
Where it loses points
- Primarily a nutrition program; GLP-1s are a secondary track
- Distributed via employers and health plans, no direct cash-pay
- Deliberately discourages GLP-1 use for most members
- GLP-1 access depends on the specific program the plan selects
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.